JP2011157378A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157378A5
JP2011157378A5 JP2011082497A JP2011082497A JP2011157378A5 JP 2011157378 A5 JP2011157378 A5 JP 2011157378A5 JP 2011082497 A JP2011082497 A JP 2011082497A JP 2011082497 A JP2011082497 A JP 2011082497A JP 2011157378 A5 JP2011157378 A5 JP 2011157378A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
chain
humanized monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011082497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011157378A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157378A publication Critical patent/JP2011157378A/ja
Publication of JP2011157378A5 publication Critical patent/JP2011157378A5/ja
Withdrawn legal-status Critical Current

Links

JP2011082497A 2002-06-28 2011-04-04 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 Withdrawn JP2011157378A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39302102P 2002-06-28 2002-06-28
US60/393,021 2002-06-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004517494A Division JP2005535636A (ja) 2002-06-28 2002-11-27 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013086246A Division JP2013139478A (ja) 2002-06-28 2013-04-17 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法

Publications (2)

Publication Number Publication Date
JP2011157378A JP2011157378A (ja) 2011-08-18
JP2011157378A5 true JP2011157378A5 (https=) 2012-07-12

Family

ID=30000962

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2004517494A Withdrawn JP2005535636A (ja) 2002-06-28 2002-11-27 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2004518039A Withdrawn JP2006508039A (ja) 2002-06-28 2003-06-27 多発性硬化症を治療する方法
JP2009284862A Withdrawn JP2010132660A (ja) 2002-06-28 2009-12-16 多発性硬化症を治療する方法
JP2011082497A Withdrawn JP2011157378A (ja) 2002-06-28 2011-04-04 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2012217520A Withdrawn JP2013032372A (ja) 2002-06-28 2012-09-28 多発性硬化症を治療する方法
JP2013086246A Pending JP2013139478A (ja) 2002-06-28 2013-04-17 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2014147314A Expired - Lifetime JP5905534B2 (ja) 2002-06-28 2014-07-18 多発性硬化症を治療する方法
JP2016030540A Withdrawn JP2016145220A (ja) 2002-06-28 2016-02-22 多発性硬化症を治療する方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2004517494A Withdrawn JP2005535636A (ja) 2002-06-28 2002-11-27 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2004518039A Withdrawn JP2006508039A (ja) 2002-06-28 2003-06-27 多発性硬化症を治療する方法
JP2009284862A Withdrawn JP2010132660A (ja) 2002-06-28 2009-12-16 多発性硬化症を治療する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2012217520A Withdrawn JP2013032372A (ja) 2002-06-28 2012-09-28 多発性硬化症を治療する方法
JP2013086246A Pending JP2013139478A (ja) 2002-06-28 2013-04-17 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2014147314A Expired - Lifetime JP5905534B2 (ja) 2002-06-28 2014-07-18 多発性硬化症を治療する方法
JP2016030540A Withdrawn JP2016145220A (ja) 2002-06-28 2016-02-22 多発性硬化症を治療する方法

Country Status (15)

Country Link
US (11) US7575742B2 (https=)
EP (3) EP3269377A1 (https=)
JP (8) JP2005535636A (https=)
AU (3) AU2002368055B2 (https=)
CA (3) CA2490804C (https=)
CY (2) CY2016043I2 (https=)
DK (2) DK1539200T3 (https=)
ES (2) ES2474718T3 (https=)
HK (1) HK1249850A1 (https=)
HU (2) HUE036677T2 (https=)
IL (2) IL165973A (https=)
LU (1) LU93315I2 (https=)
PT (2) PT1539200E (https=)
SI (2) SI1539200T1 (https=)
WO (2) WO2004002500A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261537A3 (en) * 2001-04-26 2012-06-13 Fallbrook Technologies Inc. Continuously variable transmission
AU2002368055B2 (en) * 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
AU2006204937B2 (en) 2005-01-12 2011-02-10 Biogen Ma Inc. Method for delivering Interferon-beta
US20080279819A1 (en) * 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
RU2011111391A (ru) * 2008-08-28 2012-10-10 Эбботт Байотерапьютикс Корп. (Us) Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r
WO2010045265A1 (en) * 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
WO2010068923A2 (en) * 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
CA2771335A1 (en) * 2009-08-31 2011-03-03 Abbott Biotherapeutics Corp. Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
CA2844662A1 (en) 2011-08-08 2013-02-14 Abbvie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
DE102017104088A1 (de) * 2017-02-28 2018-08-30 L&O Hunting Group GmbH Integralschalldämpfer für einen Gewehrlauf
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2021026362A1 (en) * 2019-08-07 2021-02-11 Edifice Health, Inc. Treatment of prevention of cardiovascular disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4819150A (en) 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5620686A (en) * 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
US5840496A (en) * 1990-10-09 1998-11-24 Chiron Corporation Method for diagnosing endometrial cancer
FR2672291A1 (fr) 1991-01-31 1992-08-07 Inst Nat Sante Rech Med Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale.
GB9115010D0 (en) 1991-07-11 1991-08-28 Wellcome Found Antibody
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5571507A (en) 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
EP0699077B1 (en) 1993-05-07 2001-10-31 Akzo Nobel N.V. Hiv immunogenic complexes
WO1995005734A1 (en) 1993-08-27 1995-03-02 The Pillsbury Company Mechanical gas flushing system
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
AU3710597A (en) * 1997-08-06 1999-03-01 Laboratorio Medinfar-Produtos Farmaceuticos, Lda Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system
WO2000025816A1 (en) 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
EP1321153A4 (en) 2000-04-25 2005-02-16 Tomoaki Hoshino DRUG SUBSTANCES INTENDED FOR INTERSTITIAL PNEUMONIA, METHOD OF CONSTRUCTING AN ANIMAL MODEL OF THE DISEASE, AND SCREENING METHOD USING THE SAME
CA2443405A1 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
AU2002368055B2 (en) * 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production

Similar Documents

Publication Publication Date Title
JP2011157378A5 (https=)
JP2012121878A5 (https=)
JP2014205674A5 (https=)
JP2014074046A5 (https=)
JP2017113019A5 (https=)
JP2016116527A5 (https=)
JP2015535691A5 (https=)
RU2019140356A (ru) Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений
JP2012034692A5 (https=)
JP2013539454A5 (https=)
JP2017079785A5 (https=)
JP2012521217A5 (https=)
JP2018521691A5 (https=)
JP2016183160A5 (https=)
JP2016185981A5 (https=)
JP2012525128A5 (https=)
HRP20201729T1 (hr) Antitijela protiv aktivina a i njihova primjena
JP2011184466A5 (https=)
JP2015007098A5 (https=)
JP2014237714A5 (https=)
JP2015519052A5 (https=)
JP2015524816A5 (https=)
JP2015530399A5 (https=)
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
JP2011519571A5 (https=)